BISOGNO, Gianni, Veronique MINARD-COLIN, Ilaria ZANETTI, Andrea FERRARI, Soledad GALLEGO, Raquel Davila FAJARDO, Henry MANDEVILLE, Anna KELSEY, Rita ALAGGIO, Daniel ORBACH, van Scheltinga Sheila TERWISSCHA, Gabriela Guillen BURRIEZA, Myriam BEN-ARUSH, Heidi GLOSLI, Peter MÚDRY, Sima FERMAN, Christine DEVALCK, Anne Sophie DEFACHELLES, Johannes Hendrikus Maria MERKS and Meriel JENNEY. Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Journal of clinical oncology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2023, vol. 41, No 13, p. 2342-2350. ISSN 0732-183X. Available from: https://dx.doi.org/10.1200/JCO.22.02093.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study
Authors BISOGNO, Gianni, Veronique MINARD-COLIN, Ilaria ZANETTI, Andrea FERRARI, Soledad GALLEGO, Raquel Davila FAJARDO, Henry MANDEVILLE, Anna KELSEY, Rita ALAGGIO, Daniel ORBACH, van Scheltinga Sheila TERWISSCHA, Gabriela Guillen BURRIEZA, Myriam BEN-ARUSH, Heidi GLOSLI, Peter MÚDRY (203 Czech Republic, belonging to the institution), Sima FERMAN, Christine DEVALCK, Anne Sophie DEFACHELLES, Johannes Hendrikus Maria MERKS and Meriel JENNEY.
Edition Journal of clinical oncology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2023, 0732-183X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 45.300 in 2022
RIV identification code RIV/00216224:14110/23:00133412
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1200/JCO.22.02093
UT WoS 001030226300009
Keywords in English Nonmetastatic Rhabdomyosarcoma; Children
Tags 14110321, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 14/2/2024 09:40.
Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The RMS2005 study included two phase III randomized trials for high-risk (HR) and observational trials for low (LR), standard (SR), and very high-risk (VHR) patients who have been partially reported. Herein, we present a comprehensive report of results achieved for the complete unselected nonmetastatic cohort and analyze the evolution of treatment in comparison with previous European protocols. After a median follow-up of 73.1 months, the 5-year event-free survival (EFS) and overall survival (OS) of the 1,733 patients enrolled were 70.7% (95% CI, 68.5 to 72.8) and 80.4% (95% CI, 78.4 to 82.3), respectively. The results by subgroup: LR (80 patients) EFS 93.7% (95% CI, 85.5 to 97.3), OS 96.7% (95% CI, 87.2 to 99.2); SR (652 patients) EFS 77.4% (95% CI, 73.9 to 80.5), OS 90.6% (95% CI, 87.9 to 92.7); HR (851 patients) EFS 67.3% (95% CI, 64.0 to 70.4), OS 76.7% (95% CI, 73.6 to 79.4); and VHR (150 patients) EFS 48.8% (95% CI, 40.4 to 56.7), OS 49.7% (95% CI, 40.8 to 57.9). The RMS2005 study demonstrated that 80% of children with localized rhabdomyosarcoma could be long-term survivors. The study has established the standard of care across the European pediatric Soft tissue sarcoma Study Group countries with the confirmation of a 22-week vincristine/actinomycin D regimen for LR patients, the reduction of the cumulative ifosfamide dose in the SR group, and for HR disease, the omission of doxorubicin and the addition of maintenance chemotherapy.
Links
MUNI/A/1395/2022, interní kód MUName: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“
Investor: Masaryk University
PrintDisplayed: 13/7/2024 02:56